Daniel Lee Flynn Sells 152,927 Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) insider Daniel Lee Flynn sold 152,927 shares of Deciphera Pharmaceuticals stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.91, for a total transaction of $7,479,659.57.

Daniel Lee Flynn also recently made the following trade(s):

  • On Monday, October 28th, Daniel Lee Flynn sold 29,820 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $44.34, for a total transaction of $1,322,218.80.

Shares of NASDAQ:DCPH opened at $48.91 on Friday. The firm has a market capitalization of $2.49 billion, a P/E ratio of -17.34 and a beta of 1.96. Deciphera Pharmaceuticals Inc has a 12 month low of $19.69 and a 12 month high of $49.97. The company’s fifty day moving average price is $38.24 and its 200 day moving average price is $29.65.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Monday, November 4th. The company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.09). Research analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.25 EPS for the current fiscal year.

Several research firms have recently issued reports on DCPH. Svb Leerink raised shares of Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating and lifted their price objective for the stock from $29.00 to $34.00 in a research report on Tuesday, October 29th. Leerink Swann raised shares of Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating in a research report on Tuesday, October 29th. JMP Securities lifted their price objective on shares of Deciphera Pharmaceuticals from $45.00 to $54.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 5th. Guggenheim lifted their price objective on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Finally, ValuEngine cut shares of Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, October 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $49.31.

A number of hedge funds have recently added to or reduced their stakes in the stock. Alps Advisors Inc. boosted its holdings in Deciphera Pharmaceuticals by 22.4% during the third quarter. Alps Advisors Inc. now owns 97,809 shares of the company’s stock worth $3,320,000 after buying an additional 17,884 shares in the last quarter. California Public Employees Retirement System purchased a new stake in Deciphera Pharmaceuticals during the third quarter worth about $294,000. Granite Point Capital Management L.P. purchased a new stake in Deciphera Pharmaceuticals during the third quarter worth about $1,425,000. Rhumbline Advisers boosted its holdings in Deciphera Pharmaceuticals by 38.4% during the third quarter. Rhumbline Advisers now owns 22,493 shares of the company’s stock worth $763,000 after buying an additional 6,245 shares in the last quarter. Finally, Strs Ohio boosted its holdings in Deciphera Pharmaceuticals by 82.1% during the third quarter. Strs Ohio now owns 19,300 shares of the company’s stock worth $655,000 after buying an additional 8,700 shares in the last quarter. 43.97% of the stock is currently owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

See Also: Stock Symbols Definition, Examples, Lookup

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.